These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39213066)

  • 1. Impact of Preanalytical Procedures on Complement Biomarkers in Cerebrospinal Fluid and Plasma from Controls and Alzheimer's Disease Patients.
    Gutierrez J; Kurz C; Sandoval C; Edmonds R; Bittner T; Perneczky R; Biever A
    J Alzheimers Dis; 2024; 101(2):563-576. PubMed ID: 39213066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab.
    Sandoval C; Lee J; Toth B; Nagaraj R; Schauer SP; Hoffman J; Calderon E; Kollmorgen G; Sanabria Bohórquez SM; Monteiro C; Teng E; Hanson JE; Yeh FL; Gutierrez J; Biever A
    Alzheimers Dement; 2024 Nov; 20(11):7940-7953. PubMed ID: 39369294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
    Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR
    Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid C3a increases with age, but does not increase further in Alzheimer's disease.
    Loeffler DA; Brickman CM; Juneau PL; Perry MF; Pomara N; Lewitt PA
    Neurobiol Aging; 1997; 18(5):555-7. PubMed ID: 9390784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review.
    Hansson O; Mikulskis A; Fagan AM; Teunissen C; Zetterberg H; Vanderstichele H; Molinuevo JL; Shaw LM; Vandijck M; Verbeek MM; Savage M; Mattsson N; Lewczuk P; Batrla R; Rutz S; Dean RA; Blennow K
    Alzheimers Dement; 2018 Oct; 14(10):1313-1333. PubMed ID: 29940161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation.
    Pfeifer PH; Kawahara MS; Hugli TE
    Clin Chem; 1999 Aug; 45(8 Pt 1):1190-9. PubMed ID: 10430784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology.
    Westwood S; Liu B; Baird AL; Anand S; Nevado-Holgado AJ; Newby D; Pikkarainen M; Hallikainen M; Kuusisto J; Streffer JR; Novak G; Blennow K; Andreasson U; Zetterberg H; Smith U; Laakso M; Soininen H; Lovestone S
    Alzheimers Res Ther; 2017 Apr; 9(1):31. PubMed ID: 28441961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of cerebrospinal fluid complement proteins with Alzheimer's pathology, cognition, and brain structure in non-dementia elderly.
    Li M; Ma YH; Guo Y; Liu JY; Tan L;
    Alzheimers Res Ther; 2024 Jan; 16(1):12. PubMed ID: 38238858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid.
    Le Bastard N; De Deyn PP; Engelborghs S
    Clin Chem; 2015 May; 61(5):734-43. PubMed ID: 25869575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexually Dimorphic Association of Circulating Plasminogen Activator Inhibitor-1 Levels and Body Mass Index with Cerebrospinal Fluid Biomarkers of Alzheimer's Pathology in Preclinical Alzheimer's Disease.
    Eruysal E; Ravdin L; Zhang C; Kamel H; Iadecola C; Ishii M
    J Alzheimers Dis; 2023; 91(3):1073-1083. PubMed ID: 36565112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.
    Craig-Schapiro R; Kuhn M; Xiong C; Pickering EH; Liu J; Misko TP; Perrin RJ; Bales KR; Soares H; Fagan AM; Holtzman DM
    PLoS One; 2011 Apr; 6(4):e18850. PubMed ID: 21526197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
    De Vos A; Jacobs D; Struyfs H; Fransen E; Andersson K; Portelius E; Andreasson U; De Surgeloose D; Hernalsteen D; Sleegers K; Robberecht C; Van Broeckhoven C; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
    Alzheimers Dement; 2015 Dec; 11(12):1461-1469. PubMed ID: 26092348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.
    Patra K; Soosaipillai A; Sando SB; Lauridsen C; Berge G; Møller I; Grøntvedt GR; Bråthen G; Begcevic I; Moussaud S; Minthon L; Hansson O; Diamandis EP; White LR; Nielsen HM
    Alzheimers Res Ther; 2018 Jan; 10(1):9. PubMed ID: 29378650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
    Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
    J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease.
    Bonham LW; Desikan RS; Yokoyama JS;
    Acta Neuropathol Commun; 2016 Jun; 4(1):65. PubMed ID: 27357286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
    Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
    Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.
    Teunissen CE; Chiu MJ; Yang CC; Yang SY; Scheltens P; Zetterberg H; Blennow K
    J Alzheimers Dis; 2018; 62(4):1857-1863. PubMed ID: 29614646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.